ProShare Advisors
IMVT icon

ProShare Advisors’s Immunovant IMVT Stock Holding History

ProShare Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$609K Buy
18,018
+114
+0.6% +$4.49K ﹤0.01% 921
2026
Q2 		$690K Sell
17,904
-3,017
-14% -$91.9K ﹤0.01% 922
2026
Q1 		$520K Buy
20,921
+368
+2% +$9.5K ﹤0.01% 1040
2025
Q4 		$522K Buy
20,553
+2,660
+15% +$59.3K ﹤0.01% 1113
2025
Q3 		$288K Sell
17,893
-2,500
-12% -$40.5K ﹤0.01% 1455
2025
Q2 		$326K Buy
20,393
+165
+0.8% +$2.5K ﹤0.01% 1385
2025
Q1 		$346K Sell
20,228
-3,072
-13% -$64.3K ﹤0.01% 1319
2024
Q4 		$577K Buy
23,300
+3,681
+19% +$104K ﹤0.01% 1186
2024
Q3 		$559K Buy
19,619
+3,375
+21% +$100K ﹤0.01% 1075
2024
Q2 		$429K Sell
16,244
-3,633
-18% -$103K ﹤0.01% 1059
2024
Q1 		$642K Buy
19,877
+1,703
+9% +$62.1K ﹤0.01% 953
2023
Q4 		$766K Buy
18,174
+2,620
+17% +$96.4K ﹤0.01% 830
2023
Q3 		$597K Buy
15,554
+99
+0.6% +$2.24K ﹤0.01% 851
2023
Q2 		$293K Buy
15,455
+1,193
+8% +$22.2K ﹤0.01% 1287
2023
Q1 		$221K Sell
14,262
-2,147
-13% -$37.3K ﹤0.01% 1392
2022
Q4 		$291K Buy
16,409
+2,186
+15% +$27.5K ﹤0.01% 1252
2022
Q3 		$80K Buy
14,223
+659
+5% +$3.22K ﹤0.01% 1600
2022
Q2 		$53K Sell
13,564
-6,090
-31% -$26.3K ﹤0.01% 1696
2022
Q1 		$108K Sell
19,654
-5,301
-21% -$33K ﹤0.01% 2012
2021
Q4 		$212K Sell
24,955
-4,746
-16% -$39.2K ﹤0.01% 1991
2021
Q3 		$258K Buy
29,701
+2,366
+9% +$21.3K ﹤0.01% 1653
2021
Q2 		$289K Buy
27,335
+3,758
+16% +$52.5K ﹤0.01% 1921
2021
Q1 		$378K Buy
23,577
+162
+0.7% +$4.27K ﹤0.01% 1652
2020
Q4 		$1.08M Buy
+23,415
New +$1.08M ﹤0.01% 843

Other funds holding IMVT

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Arizona State Retirement System
Arizona State Retirement System Phoenix, Arizona $20.3B AUM 36.55% 1-Year Est. Return
Kestra Advisory Services
Kestra Advisory Services Austin, Texas $35.1B AUM 20.13% 1-Year Est. Return

ProShare Advisors's IMVT Position: Q3 2026 in Review

ProShare Advisors increased its Immunovant (IMVT) stake by 0.64% in Q3 2026, buying an estimated $4.49K and bringing the position to 18,018 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #921.

ProShare Advisors first reported a position in IMVT in Q4 2020 and has held it in 24 quarters since. The position peaked at $1.08M in Q4 2020. 46 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • ProShare Advisors held 18,018 shares of Immunovant worth $609K as of Q3 2026.
  • ProShare Advisors bought 114 Immunovant shares in Q3 2026, an estimated $4.49K.
  • Immunovant made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #921 holding.
  • ProShare Advisors first reported a position in Immunovant in Q4 2020 and has held it in 24 quarters since.
  • ProShare Advisors's Immunovant position peaked at $1.08M in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.